were designed and synthesized. In vitro inhibition experiments demonstrated that 3, 12c, and BIBD-399 have high affinity for A2AR. [18F]3 and [18F]BIBD-399 were successfully synthesized. In terms of biological distribution, the brain uptake of [18F]MNI-444 exhibits greater than that of [18F]3 and [18F]BIBD-399. PET imaging shows that [18F]3 is off-target in the brain, while [18F]BIBD-399 and [18F]MNI-444
通过修饰靶向A 2A R
拮抗剂和示踪剂的结构,设计并合成了新化合物3、7a、9、12c和BIBD - 399。体外抑制实验表明3 、 12c和BIBD-399 对A 2A R 具有高亲和力。成功合成了[ 18 F]3和[ 18 F]BIBD-399。就
生物分布而言,[ 18 F]MNI-444的脑摄取表现出大于[ 18 F]3和[ 18 F]BIBD-399。 PET 成像显示[ 18 F]3在大脑中
脱靶,而 [ 18 F]BIBD-399 和 [ 18 F]MNI-444 可以在 A 2A R 高表达区域特异性成像。不同的是,[ 18 F]BIBD-399在给药后10分钟内即可在目标区域迅速达到平衡,而[ 18 F]MNI-444在给药后2小时内表现出缓慢增加的趋势。 [ 18 F]BIBD-399主要经肝、肾代谢,体内无明显
脱氟作用。另外的体外放射自显影显示,[ 18 F]BIBD-399